• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·KLRA
Held by 1 Guru
Share

Kailera Therapeutics, Inc. Stocks

$ 16.43Last Updated 08.09.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 2.10B

$ 16.43
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.01%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.01%

Latest news

17.08.2026 17:07

Motley Fool sees big risks and big upside in anti-obesity drugmakers Viking, Kailera

19.04.2026 22:00

Record listing since the 20th century and Ekman's roadshow: what's important about IPOs by April 19

17.04.2026 15:00

Kailera Therapeutics IPO: Shares of obesity drugmaker start trading

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of KLRA is 45.2 and suggests 178% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.09.2026 18:24

Signet Jewelry Shares Are on Track for Their Best Day of the Year Following a Strong Earnings Report

09.09.2026 18:02

The wave of attacks by Iran and the U.S. on ships near the Strait of Hormuz has reached its peak since the start of the war

09.09.2026 17:04

Novartis's failed trials sent shares of mid-cap biotech company Dyne plummeting. The two companies have similar drugs.

09.09.2026 16:15

The dollar has fallen to a seven-month low. What is driving it down?

09.09.2026 15:41

Morning in New York: Brent Puts Investors to the Test

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026